DADC
PACB icon

D.A. Davidson & Co’s Pacific Biosciences PACB Stock Holding History

D.A. Davidson & Co’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,000
Closed -$5K – 2415
2017
Q1 		$5K Hold
1,000
– – ﹤0.01% 2175
2016
Q4 		$3K Hold
1,000
– – ﹤0.01% 2325
2016
Q3 		$8K Buy
+1,000
New +$8.36K ﹤0.01% 2104

Other funds holding PACB

MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

D.A. Davidson & Co's PACB Position: Q2 2017 in Review

D.A. Davidson & Co sold out of Pacific Biosciences (PACB) in Q2 2017, closing a stake of 1,000 shares — an estimated $5K sold.

D.A. Davidson & Co first reported a position in PACB in Q3 2016 and held it in 3 quarters. The position peaked at $8K in Q3 2016. 107 funds tracked by Wall St. Rank hold PACB as of Q2 2017.

  • D.A. Davidson & Co reported no remaining Pacific Biosciences position as of Q2 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 1,000 Pacific Biosciences shares in Q2 2017, an estimated $5K.
  • D.A. Davidson & Co first reported a position in Pacific Biosciences in Q3 2016 and held it in 3 quarters.
  • D.A. Davidson & Co's Pacific Biosciences position peaked at $8K in Q3 2016.
  • 107 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2017.

Based on D.A. Davidson & Co's 13F filing for Q2 2017, filed 11 Aug 2017.